Search | Clinical Trials Finder

Conditions: Anterior Cruciate Ligament Rupture
Interventions: Adductor Canal Nerve Block, Ropivacaine injection; Procedure · Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Asthma
Interventions: BI 671800, Fluticasone propionate placebo, Fluticasone propionate, BI 671800 Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 40
States / cities: Tucson, Arizona • Cypress, California • Los Angeles, California + 34 more

Conditions: Hepatic Impairment, Healthy Volunteers
Interventions: Mobocertinib; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Hialeah, Florida • Orlando, Florida

Conditions: Osteoporosis
Interventions: SB-751689; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 35 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Migraines, Bleeding, Spotting
Interventions: frovatriptan, placebo; Drug
Lead sponsor: Scott and White Hospital & Clinic; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Healthy Participants
Interventions: Brensocatib Oral Solution, Brensocatib Oral Tablet; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic
Interventions: LAM-002A, Rituximab, Atezolizumab; Drug
Lead sponsor: IRulya Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 11
States / cities: Huntsville, Alabama • Jacksonville, Florida • Atlanta, Georgia + 7 more

Conditions: Drug Resistant Epilepsy
Interventions: Cannabidiol; Drug
Lead sponsor: John; Other
Eligibility: 5 Years to 19 Years
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Diabetes Mellitus, Type 2
Interventions: BI 10773, BI 10773 Placebo, BI 10773 / BI 1356, BI 10773 / BI 1356 Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 708 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 24
States / cities: Chino, California • Huntington Beach, California • San Diego, California + 20 more

Conditions: Tumor Lysis Syndrome, Cancer, Hyperuricemia
Interventions: Rasburicase (SR29142), Allopurinol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 15
States / cities: Berkeley, California • Los Angeles, California • Denver, Colorado + 12 more

Conditions: Alzheimer's Disease
Interventions: J147, Placebo; Drug
Lead sponsor: Abrexa Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Type II Diabetes, Periodontal Disease
Interventions: Motivational Interviewing, Dental cleaning; Behavioral · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
Interventions: ONC-392, Pembrolizumab, Docetaxel; Drug
Lead sponsor: OncoC4, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 733 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 33
States / cities: Springdale, Arkansas • Davis, California • Downey, California + 27 more

Conditions: Parkinson Disease
Interventions: PRIM-DJ2727, Placebo oral capsule; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 55 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Asthma, Wheezing
Interventions: Azithromycin, Prednisolone, Placebo Azithromycin, Placebo Prednisolone; Drug · Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 12 Months to 71 Months
Enrollment: 607 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 16
States / cities: Tucson, Arizona • Oakland, California • San Francisco, California + 11 more

Conditions: HIV Infections
Interventions: CD4-IgG, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: San Diego, California • Miami, Florida • Worcester, Massachusetts

Conditions: Metastatic Uveal Melanoma
Interventions: FHD-286; Drug
Lead sponsor: Foghorn Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 9
States / cities: Los Angeles, California • Miami, Florida • Boston, Massachusetts + 4 more

Conditions: Hematologic Malignancies
Interventions: TXA127; Drug
Lead sponsor: Tarix Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Smoking Cessation
Interventions: APD356-lorcaserin hydrochloride, Placebo; Drug
Lead sponsor: Arena Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 603 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 31
States / cities: Encino, California • Escondido, California • Los Alamitos, California + 27 more

Conditions: Myeloma
Interventions: Pomalidomide, Dexamethasone, Cyclophosphamide; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 3
States / cities: San Francisco, California • Tampa, Florida • New York, New York

Conditions: Virus, HSV-1, Herpes Simplex 1, Herpes Simplex Labialis
Interventions: Purell Hand Sanitizer, Medical Grade Mineral Oil; Drug
Lead sponsor: Leciel Bono; Other
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Pocatello, Idaho • St. George, Utah

Conditions: Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting, HIV Infections
Interventions: Dronabinol, Placebo; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 36
States / cities: Bakersfield, California • Fresno, California • Los Angeles, California + 27 more

Conditions: Rett Syndrome, RTT
Interventions: GWP42003-P, Placebo; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 14
States / cities: Birmingham, Alabama • San Diego, California • Aurora, Colorado + 11 more

Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Interventions: Liprotamase, Placebo; Drug
Lead sponsor: Anthera Pharmaceuticals; Industry
Eligibility: 7 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 27
States / cities: Birmingham, Alabama • Palo Alto, California • Denver, Colorado + 23 more

Search by objective public record fields.

Pain Management of ACL Reconstruction

BI 671800 ED in Steroid-naive Asthmatic Patients

A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function

A Study To Investigate The Metabolism And Excretion Of 14C SB-751689 Given To Healthy Males And Postmenopausal Women

Prevention of Menstrual Migraines: Using Frovatriptan or Placebo During Hormone Free Intervals

A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants

A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma

Cannabidiol for Drug Resistant Pediatric Epilepsy (Expanded Access Use)

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147

Providing Preventive Periodontal Treatment to Hospitalized Patients With Diabetes

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Study of the Fecal Microbiome in Patients With Parkinson's Disease

Treatment of Preschool Children With Upper Respiratory Tract Illnesses Using Azythromycin and Lower Respiratory Tract Symptoms Using Oral Corticosteroids.

A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4-Immunoglobulin G (rCD4-IgG) Administered by Intravenous Bolus Injection in Combination With Oral Zidovudine in Patients With AIDS and AIDS-Related Complex

FHD-286 in Subjects With Metastatic Uveal Melanoma

Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation

A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation

Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide

Hand Sanitizer Use for Herpes Simplex Virus-1

Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting

Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency